Provided by Tiger Trade Technology Pte. Ltd.

CTI BIOPHARMA

9.09
0.0000
Volume:- -
Turnover:103.82M
Market Cap:1.20B
PE:-16.10
High:9.09
Open:9.09
Low:9.09
Close:9.09
52wk High:9.10
52wk Low:4.01
Shares:131.88M
Float Shares:99.89M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5646
EPS(LYR):-0.8108
ROE:-1018.75%
ROA:-28.58%
PB:-47.29
PE(LYR):-11.21

Loading ...

Company Profile

Company Name:
CTI BIOPHARMA
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.